Abstract
IntroductionSubcutaneous emicizumab prophylaxis substantially reduces bleeding episodes in patients with haemophilia A (PwHA) and factor VIII inhibitor. However, thrombotic events occurred in some PwHA with inhibitor who had received high...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have